4-(氯甲基)-2-甲氧基-1-硝基苯 | 68837-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(氯甲基)-2-甲氧基-1-硝基苯
• 英文名称: 3-methoxy-4-nitrobenzyl chloride
• 英文别名: 4-(Chloromethyl)-2-methoxy-1-nitrobenzene
• CAS: 68837-96-7
• 化学式: C₈H₈ClNO₃
• mdl: MFCD09745030
• 分子量: 201.609
• InChiKey: YPGTXBMNSXUGTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(氯甲基)-2-甲氧基-1-硝基苯 在 硫酸 、 palladium 10% on activated carbon 、 guanidine nitrate 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 10.0h， 生成 4-[(dimethylamino)methyl]-2-methoxy-5-nitroaniline
  参考文献：
  名称：

  Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

  摘要：

  A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design.

  DOI：

  10.1021/jm400822z
• 作为产物：
  描述：

  3-甲氧基-4-硝基苯甲醇 在 N-氯代丁二酰亚胺 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以84%的产率得到4-(氯甲基)-2-甲氧基-1-硝基苯
  参考文献：
  名称：

  [EN] 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] DÉRIVÉS DE 2-[(2-{PHÉNYLAMINO}-1H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]BENZAMIDE EN TANT QU'INHIBITEUR D'IGF-1R POUR LE TRAITEMENT DU CANCER

  摘要：

  新型吡咯吡嘧啶如公式(I)所示，及其药用可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。

  公开号：

  WO2009020990A1

文献信息

• Imidazopyridine Kinase Inhibitors
  申请人：Kuntz Kevin

  公开号：US20080300242A1

  公开（公告）日：2008-12-04

  The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了咪唑并吡啶化合物、含有该化合物的组合物，以及它们的制备方法和作为药物的使用方法。
• [EN] MACROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE MACROCYCLIQUES
  申请人：OSI PHARMACEUTICALS LLC

  公开号：WO2012074951A1

  公开（公告）日：2012-06-07

  Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.

  式(I)的化合物：其中变量在此处定义，并且其药用盐、合成、中间体、配方和治疗疾病的方法，包括对FAK抑制有益的癌症。
• [EN] INSECTICIDAL PHTHALAMIDE DERIVATIVES<br/>[FR] DERIVES DE PHTALAMIDES INSECTICIDES
  申请人：BAYER CROPSCIENCE AG

  公开号：WO2004080984A1

  公开（公告）日：2004-09-23

  Novel insecticidal phthalamide derivatives of the formula (I), in which is a 5- or 6- membered heterocyclic group, a plurality of processes for preparing these compounds and their use for controlling pests.

  新型杀虫酰胺衍生物的化学式（I），其中是一个5-或6-成员杂环基团，多种制备这些化合物的过程以及它们用于控制害虫的用途。
• Synthesis of 3-Benzylphthalide Derivatives by Using a TDAE Strategy
  作者：Patrice Vanelle、Maroua Ibrahimi、Omar Khoumeri、Raoudha Abderrahim、Thierry Terme

  DOI：10.1055/a-1290-8349

  日期：2021.2

  A one-pot synthesis of new 3-benzylphthalide derivatives was developed by using a strategy based on tetrakis(dimethylamino)ethylene (TDAE). The reactions in the presence of TDAE of substituted benzyl chlorides with methyl 2-formylbenzoate or of substituted methyl-2-formylbenzoates with 4-nitrobenzyl chloride furnished the corresponding isobenzofuran-1(3H)-one products in moderate to good yields.

  使用基于四（二甲氨基）乙烯 (TDAE) 的策略开发了新型 3-苄基苯酞衍生物的一锅法合成。在 TDAE 存在下，取代苄基氯与 2-甲酰基苯甲酸甲酯或取代 2-甲酰基苯甲酸甲酯与 4-硝基苄基氯的反应以中等至良好的产率提供相应的异苯并呋喃-1(3H)-酮产物。
• Novel thiourea compounds and the pharmaceutical compositions containing the same
  申请人：——

  公开号：US20030212140A1

  公开（公告）日：2003-11-13

  The present invention relates to thiourea compounds and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as an antagonist against vanilloid receptor (VR) and the pharmaceutical compositions thereof. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及硫脲化合物和含有它们的制药组合物，特别是作为vanilloid受体（VR）拮抗剂的新型硫脲化合物及其制药组合物。作为与vanilloid受体活性相关的疾病，可以列举出疼痛、急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病变、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病等。本发明提供了一种预防或治疗这些疾病的制药组合物。